BioCentury | Aug 28, 2020
Distillery Therapeutics

Exon skipping therapy for Batten disease

DISEASE CATEGORY: Neurology INDICATION: Neurology Antisense oligonucleotides that induce exon skipping in lysosomal membrane protein CLN3 could treat CLN3 Batten disease, a neurodegenerative lysosomal...
BioCentury | Aug 25, 2020

Seeing path for cholesterol-lowering program, Forbion launches start-up to house former Dezima molecule

Five years after reaping a strong return from cholesterol-lowering molecule obicetrapib, Forbion is again investing in the program based on a belief it can serve some dyslipidemia patients where others in its class fell short....
BioCentury | Jul 25, 2020
Product Development

NIH, HHS fast-tracking point-of-care, pooled tech as way out of testing crunch

The U.S. government is taking non-conventional paths to point-of-care and pooled technologies in its push to bulk up and speed up the country’s strained COVID-19 testing capacity. In HHS’s case, the department is scrambling to...
BioCentury | Jul 3, 2020

On heels of $100M raise, Annexon joins burgeoning IPO queue

Two days after raising $100 million in a series D round heavy with crossover investors, Annexon has filed to go public on NASDAQ. The filing adds to a burgeoning IPO queue and caps another busy...
BioCentury | Jun 27, 2020
Product Development

Modeling harmony: learning from preclinical coordination of COVID-19 countermeasures

The all-hands-on-deck COVID-19 response provides a glimpse of what’s possible when drug developers converge around solving a problem. One of the most important developments might be in preclinical research where consensus on harmonized models and...
BioCentury | Jun 10, 2020
Emerging Company Profile

Autobahn: fine-tuning thyroid agonism to remyelinate axons

Autobahn, which launched with a $76 million series B Tuesday, joins at least six other companies with disclosed remyelination programs for multiple sclerosis. But the biotech thinks its prodrug, slated to enter the clinic next...
BioCentury | Jun 4, 2020
Product Development

June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more

BeiGene’s BTK inhibitor gets first China approval BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) said China’s National Medical Products Administration approved Brukinsa zanubrutinib in two cancer indications: chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma...
BioCentury | Apr 15, 2020
Emerging Company Profile

Backed by Third Rock-led syndicate, MOMA seeks new ATP-powered targets by interrogating 'molecular machines'

Third Rock Ventures led a syndicate that invested $86 million in a series A round for MOMA Therapeutics, a newly launched start-up that will seek to interrogate a class of "molecular machines" that drive cellular...
BioCentury | Apr 4, 2020

Investors are seeking only one thing: a sign the pandemic tide is shifting

The usual clinical and commercial catalysts are taking a back seat in the second quarter as buysiders are almost solely focused on COVID-19 milestones that will stabilize the market. On the other hand, the virtual...
BioCentury | Mar 13, 2020
Tools & Techniques

How to feed the machine: lessons from an AI antibiotics study

The recent AI-based discovery of broad-spectrum antibiotic candidates highlights the potential of new machine learning methods to find compounds humans might otherwise miss, but ups the ante on the quality and diversity of input data...
Items per page:
1 - 10 of 746